No quarterly revenue total was found in PEPGEN INC.'s SEC filings.
Pepgen Inc. (PEPG) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$15.8 million. As of Jun 30, 2026 it held $117.2 million in cash and investments and $16.1 million in total debt.
Revenue
—
Net income
$-17.81M
+22.8% vs year-ago quarter
Operating cash flow
$-15.81M
+33.0% vs year-ago quarter
Free cash flow
$-15.84M
+33.0% vs year-ago quarter
EPS
$-0.26
+62.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
69.26M
+111.2% vs year-ago quarter
Net cash
$101.14M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PEPG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1835597
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$18.9M | -$18.9M | -$19.7M | -$18.7M | -$23.9M |
| Net income | -$17.8M | -$17.8M | -$18.3M | -$18.0M | -$23.1M |
| Diluted EPS | -$0.26 | -$0.26 | -$0.27 | -$0.52 | -$0.70 |
| Operating cash flow | -$15.8M | -$18.4M | -$15.8M | -$19.3M | -$23.6M |
| Free cash flow | -$15.8M | -$18.4M | -$15.8M | -$19.4M | -$23.6M |
| Total assets | $141.4M | $156.3M | $173.9M | $190.1M | $102.2M |
| Total liabilities | $21.9M | $22.3M | $26.5M | $26.9M | $31.1M |
| Stockholders' equity | $119.5M | $134.0M | $147.4M | $163.1M | $71.2M |
| Cash and investments | $117.2M | $132.3M | $148.5M | $163.7M | $74.7M |
| Total debt | $16.1M | $16.6M | $17.0M | $17.4M | $17.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 21, 2026 | May 21, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
All 304 Pepgen Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.